cvt.com

Cv Therapeutics


CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States. CV Therapeutics developed Ranexa, a drug to treat chronic angina; and Lexiscan, an injection used as a stress agent in cardiovascular procedures. The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.
View Top Employees for Cv Therapeutics
img Website cvt.com
img Industry Biotechnology
img Location Palo Alto, California, United States
img Employees 571
img Founded 1991
img HQ 3172 Porter Drive
img Funding 0
img Competitors Roche, Agilent Technologies, Amgen, Genentech, Eurofins, Gilead Sciences,
img Website cvt.com
img Industry Biotechnology
img Location Palo Alto, California, United States
img Employees 571
img Founded 1991
img LinkedIn linkedin.com/company/cv-therapeutics
img HQ 3172 Porter Drive
img Funding 0

Top Cv Therapeutics Employees